Lugar de publicación
- Scaled average bioequivalence methods for highly variable drugs: Leveling-off soft limits and the EMA's 2010 guideline (some ways to improve its type I error control). 43(7):1475-1488. 2024
- Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs. 35(12):1933-1943. 2016